STERIS (NYSE:STE – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided EPS guidance of $8.40-$8.60 for the period, compared to the consensus EPS estimate of $8.49. The company issued revenue guidance of $4.95 billion-$4.95 billion, compared to the consensus revenue estimate of $4.98 billion.
STERIS Stock Performance
Shares of STE stock opened at $190.28 on Friday. The firm has a fifty day moving average of $172.62 and a 200-day moving average of $195.36. STERIS has a 52-week low of $159.21 and a 52-week high of $255.93. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.42 and a current ratio of 2.16.
STERIS (NYSE:STE – Get Rating) last posted its quarterly earnings results on Wednesday, November 9th. The medical equipment provider reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.01. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. STERIS had a negative net margin of 0.17% and a positive return on equity of 12.75%. The company’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.99 earnings per share. On average, equities research analysts forecast that STERIS will post 8.45 earnings per share for the current year.
STERIS Dividend Announcement
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on STE shares. Needham & Company LLC cut shares of STERIS from a buy rating to a hold rating in a research report on Friday, September 23rd. KeyCorp dropped their price objective on shares of STERIS from $240.00 to $210.00 and set an overweight rating for the company in a report on Friday, November 11th. Finally, StockNews.com cut shares of STERIS from a buy rating to a hold rating in a research note on Friday, December 2nd. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $242.40.
Institutional Trading of STERIS
Hedge funds have recently modified their holdings of the stock. Invesco Ltd. increased its stake in shares of STERIS by 89.8% in the 1st quarter. Invesco Ltd. now owns 953,983 shares of the medical equipment provider’s stock valued at $230,645,000 after buying an additional 451,235 shares during the period. Vanguard Group Inc. lifted its stake in STERIS by 1.3% in the first quarter. Vanguard Group Inc. now owns 11,525,769 shares of the medical equipment provider’s stock valued at $2,786,586,000 after buying an additional 143,253 shares in the last quarter. BNP Paribas Arbitrage SNC boosted its stake in STERIS by 280.2% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 96,390 shares of the medical equipment provider’s stock worth $16,028,000 after purchasing an additional 71,036 shares during the period. First Trust Advisors LP grew its holdings in shares of STERIS by 207.0% during the first quarter. First Trust Advisors LP now owns 103,106 shares of the medical equipment provider’s stock worth $24,928,000 after buying an additional 69,518 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of STERIS by 42.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 218,395 shares of the medical equipment provider’s stock worth $52,802,000 after acquiring an additional 64,877 shares in the last quarter. 92.04% of the stock is owned by institutional investors.
STERIS Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
- Get a free copy of the StockNews.com research report on STERIS (STE)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.